PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)

In order to explore the potential patient population who could benefit from anti PD-1/PD-L1 mono or combination therapies, this study aimed to profile a panel of immunotherapy related biomarkers (PD-1, PD-L1, CTLA-4 and CD8) and targeted therapy biomarkers (EGFR, KRAS, ALK, ROS1 and MET) in NSCLC. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Liyan, Su, Xinying, Zhang, Tianwei, Yin, Xiaolu, Zhang, Meizhuo, Fu, Haihua, Han, Hulin, Sun, Yun, Dong, Lili, Qian, Jialin, Xu, Yanhua, Fu, Xuan, Gavine, Paul R., Zhou, Yanbin, Tian, Kun, Huang, Jiaqi, Shen, Dong, Jiang, Haiyi, Yao, Yihong, Han, Baohui, Gu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432301/
https://www.ncbi.nlm.nih.gov/pubmed/28460468
http://dx.doi.org/10.18632/oncotarget.15839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432301/
https://www.ncbi.nlm.nih.gov/pubmed/28460468
http://dx.doi.org/10.18632/oncotarget.15839

Ejemplares similares